

Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

<https://marketpublishers.com/r/EFDA601282E3EN.html>

Date: February 2023

Pages: 148

Price: US\$ 3,000.00 (Single User License)

ID: EFDA601282E3EN

Abstracts

The Europe pulmonary arterial hypertension market is expected to grow from US\$ 1,959.47 million in 2022 to US\$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH—in which a family history or an identified risk factor is present—is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial

hypertension is driving the growth of the Europe pulmonary arterial hypertension market.

Europe Pulmonary Arterial Hypertension Market Overview

The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.

Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US\$ Billion)

Europe Pulmonary Arterial Hypertension Market Segmentation

The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.

Based on route of administration, the Europe pulmonary arterial hypertension market is

segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the Europe pulmonary arterial hypertension market.

Contents

1. INTRODUCTION

- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
 - 1.3.1 Europe Pulmonary Arterial Hypertension Market – By Drugs
 - 1.3.2 Europe Pulmonary Arterial Hypertension Market – By Type
 - 1.3.3 Europe Pulmonary Arterial Hypertension Market – By Route of Administration
 - 1.3.4 Europe Pulmonary Arterial Hypertension Market – By Distribution Channel
 - 1.3.5 Europe Pulmonary Arterial Hypertension Market – By Country

2. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – MARKET LANDSCAPE

- 4.1 Overview
- 4.2 Europe PEST Analysis
- 4.3 Experts Opinion

5. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – KEY MARKET DYNAMICS

- 5.1 Market Drivers
 - 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
- 5.2 Market Restraints
 - 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
- 5.3 Market Opportunities
 - 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration

5.4 Future Trend

5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension

5.5 Impact analysis

6. PULMONARY ARTERIAL HYPERTENSION MARKET – EUROPE ANALYSIS

6.1 Europe Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – REVENUE AND FORECAST TO 2028 – BY DRUGS

7.1 Overview

7.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)

7.3 Endothelin Receptor Antagonists (ERAs)

7.3.1 Overview

7.3.2 Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

7.4 Prostacyclin and Prostacyclin Analogs

7.4.1 Overview

7.4.2 Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

7.5 SGC Stimulators

7.5.1 Overview

7.5.2 sGC Stimulators: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

7.6 Pde-5 Dipsticks

7.6.1 Overview

7.6.2 Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

8. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET ANALYSIS AND FORECASTS TO 2028 – BY TYPE

8.1 Overview

8.2 Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

8.3 Branded

8.3.1 Overview

8.3.2 Branded: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

8.4 Generics

8.4.1 Overview

8.4.2 Generics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

9. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – REVENUE AND FORECAST TO 2028 – BY ROUTE OF ADMINISTRATION

9.1 Overview

9.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

9.3 Oral

9.3.1 Overview

9.3.2 Oral: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

9.4 Intravenous/ Subcutaneous

9.4.1 Overview

9.4.2 Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

9.5 Inhalational

9.5.1 Overview

9.5.2 Inhalational: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

10. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – REVENUE AND FORECAST TO 2028 – BY DISTRIBUTION CHANNEL

10.1 Overview

10.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

10.3 Hospital Pharmacies and Clinics

10.3.1 Overview

10.3.2 Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

10.4 Online Pharmacies

10.4.1 Overview

10.4.2 Online Pharmacies: Europe Pulmonary Arterial Hypertension Market – Revenue

and Forecast to 2028 (US\$ Million)

10.5 Retail Pharmacies

10.5.1 Overview

10.5.2 Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS

11.1 Europe: Pulmonary Arterial Hypertension Market

11.1.1 Overview

11.1.2 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.1.2.1 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.1.1 Overview

11.1.2.1.2 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

11.1.2.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.2.1 Overview

11.1.2.2.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

11.1.2.3 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to

2028 (US\$ Million)

11.1.2.3.1 Overview

11.1.2.3.2 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

11.1.2.4 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.4.1 Overview

11.1.2.4.2 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

11.1.2.5 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.5.1 Overview

11.1.2.5.2 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

11.1.2.6 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and

Forecast to 2028 (US\$ Million)

11.1.2.6.1 Overview

11.1.2.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US\$ Million)

11.1.2.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US\$ Million)

11.1.2.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US\$ Million)

11.1.2.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US\$ Million)

12. PULMONARY ARTERIAL HYPERTENSION MARKET – INDUSTRY LANDSCAPE

12.1 Overview

12.2 Organic Developments

12.2.1 Overview

12.3 Inorganic Developments

12.3.1 Overview

13. COMPANY PROFILES

13.1 Johnson & Johnson

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Gilead Sciences Inc

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 United Therapeutics Corp

13.3.1 Key Facts

- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Bayer AG
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
- 13.5 Novartis AG
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
- 13.6 GSK Plc
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
- 13.7 Teva Pharmaceutical Industries Ltd
 - 13.7.1 Key Facts
 - 13.7.2 Business Description
 - 13.7.3 Products and Services
 - 13.7.4 Financial Overview
 - 13.7.5 SWOT Analysis
 - 13.7.6 Key Developments
- 13.8 Lupin Ltd
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Pfizer Inc

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

14. APPENDIX

14.1 About The Insight Partners

14.2 Glossary of Terms

List Of Tables

LIST OF TABLES

Table 1. Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 2. UK Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 3. UK Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 4. UK Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 5. UK Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 6. Germany Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 7. Germany Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 8. Germany Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 9. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 10. France Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 11. France Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 12. France Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 13. France Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 14. Italy Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 15. Italy Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 16. Italy Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 17. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 18. Spain Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 19. Spain Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 20. Spain Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 21. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 22. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US\$ Million)

Table 23. Rest of Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US\$ Million)

Table 24. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US\$ Million)

Table 25. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US\$ Million)

Table 26. Organic Developments in the Europe pulmonary arterial hypertension market

Table 27. Inorganic Developments in the Europe pulmonary arterial hypertension market

Table 28. Glossary of Terms

List Of Figures

LIST OF FIGURES

- Figure 1. Europe Pulmonary Arterial Hypertension Market Segmentation
- Figure 2. Europe Pulmonary Arterial Hypertension Market – By Country
- Figure 3. Europe Pulmonary Arterial Hypertension Market Overview
- Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the Europe Pulmonary Arterial Hypertension Market
- Figure 5. UK to Show Significant Growth During Forecast Period
- Figure 6. Europe: PEST Analysis
- Figure 7. Experts Opinion
- Figure 8. Europe Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
- Figure 9. Europe Pulmonary Arterial Hypertension Market– Revenue Forecast and Analysis – 2020 - 2028
- Figure 10. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
- Figure 11. Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 12. Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 13. sGC Stimulators: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 14. Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 15. Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
- Figure 16. Branded: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 17. Generics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 18. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
- Figure 19. Oral: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 20. Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 21. Inhalational: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 22. Europe Pulmonary Arterial Hypertension Market Revenue Share, by

Distribution Channel 2021 & 2028 (%)

Figure 23. Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 24. Online Pharmacies: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 25. Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 26. Europe: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US\$ Million)

Figure 27. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

Figure 28. UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 29. Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 30. France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 31. Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 32. Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 33. Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US\$ Million)

I would like to order

Product name: Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

Product link: <https://marketpublishers.com/r/EFDA601282E3EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EFDA601282E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970